Direct-acting antiviral-based therapy for chronic hepatitis C virus in HIV-infected patients

David Del Bello, Fanny Ita Nagy, Jonathan Hand, Rabea Khedemi, Julien Lécluse-Barth, Douglas Dieterich, Lionel Piroth

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Purpose of review The aim of this review was to detail the current therapies and treatments for chronic hepatitis C virus in coinfected patients, focusing on HCV antiviral agents currently used in practice today or scheduled to enter the open market soon. Recent findings Several direct-acting antiviral (DAA) combinations show high sustained virologic response (SVR) rates in HIV/HCV-coinfected patients, which are often close to those observed in HCV-monoinfected patients. Most recommendations regarding treatment stem from trials with coinfected patients. However, data are lacking for some aspects of HCV-treatment in coinfection, so extrapolations must be made from data obtained predominately from monoinfected patients. Summary HIV/HCV-coinfected patients, who, not too long ago, had inferior outcomes in capturing SVR, now enjoy similar fates as the monoinfected patients. They should thus be prioritized for treatment, since HCV and liver disease have become major causes of morbidity and mortality in this population. However, potential drug-drug interactions between antiretroviral agents and DAAs have to be systematically anticipated before initiating HCV therapy.

Original languageEnglish (US)
Pages (from-to)337-347
Number of pages11
JournalCurrent Opinion in HIV and AIDS
Issue number5
StatePublished - Sep 1 2015
Externally publishedYes


  • Direct antiviral agents
  • HIV
  • Hepatitis C virus

ASJC Scopus subject areas

  • Immunology
  • Hematology
  • Oncology
  • Oncology(nursing)
  • Infectious Diseases
  • Virology


Dive into the research topics of 'Direct-acting antiviral-based therapy for chronic hepatitis C virus in HIV-infected patients'. Together they form a unique fingerprint.

Cite this